GLP-1 Medications Beyond Weight Loss: Heart, Brain, Blood Pressure & More

GLP-1 (glucagon-like peptide-1) is a hormone naturally released by intestinal cells after eating. It slows gastric emptying, signals fullness to the brain, and stimulates insulin release. But GLP-1 receptors aren't limited to the gut and pancreas — they're expressed across the cardiovascular system, kidneys, brain, liver, and immune cells.

Pharmaceutical GLP-1 agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) flood these receptors far more intensely and persistently than the body's own hormone. That's why their effects extend well beyond appetite — and why researchers have started running dedicated trials for cardiovascular, renal, and neurological endpoints.

The most compelling evidence for GLP-1 benefits beyond weight loss comes from the SELECT trial, published in the New England Journal of Medicine in 2023 (Lincoff et al.).

Crucially, SELECT enrolled adults without type 2 diabetes — the typical GLP-1 indication — which isolates weight-loss and direct drug effects from the glycaemic benefits that confound earlier CVOT trials like LEADER and SUSTAIN-6.

Proposed mechanisms for the cardiovascular benefit include: direct anti-inflammatory signalling via GLP-1 receptors on macrophages and cardiac muscle cells, reductions in arterial stiffness, improved endothelial nitric oxide synthesis, and lower systolic blood pressure.

A 2021 meta-analysis by Sposito et al. pooling data from 60 GLP-1 trials found a mean systolic blood pressure reduction of −3.57 mmHg (95% CI: −4.09 to −3.04) compared to placebo or active comparators. Diastolic pressure dropped by approximately −1.5 mmHg.

While modest in absolute terms, even a 3 mmHg reduction in population systolic blood pressure is estimated to reduce stroke mortality by ~8% and coronary heart disease mortality by ~5% (Whelton et al., 2002 meta-analysis). The effect is seen in hypertensive patients and those with normal baseline BP.

Migraine affects roughly 12% of the global population. Modern preventive treatments like erenumab (Aimovig) and rimegepant (Nurtec) work by blocking CGRP — calcitonin gene-related peptide, the key mediator of migraine pain.

Here's the connection to GLP-1: semaglutide has been shown in preclinical studies to suppress CGRP release from trigeminal nerve terminals — the same pathway targeted by anti-CGRP biologics. A 2022 study by Deligianni et al. reported that semaglutide reduced CGRP-induced dilation of cranial arteries in rodent models, suggesting a direct anti-migraine mechanism.

Observational clinical reports followed: several patients on GLP-1 agonists for weight management or diabetes reported a significant reduction in migraine frequency and severity. A Danish register study (Kokoti et al., 2023) found GLP-1 agonist users had lower rates of triptan prescription fills compared to matched controls, suggesting reduced acute migraine attacks.

GLP-1 receptors are expressed in the nucleus accumbens, ventral tegmental area, and prefrontal cortex — brain regions central to motivation, mood, and reward processing. This anatomical reality has fuelled intense interest in GLP-1 effects on depression, anxiety, and addiction.

Depression

A pre-specified subanalysis of the SELECT trial found that semaglutide produced significantly greater improvements in the SF-36 mental health component score compared to placebo, with effect sizes independent of weight change. In separate datasets, patients starting GLP-1 agonists for diabetes showed lower rates of antidepressant initiation at 12 months vs matched controls (Wium-Andersen et al., 2023, JAMA Network Open).

A rodent study by Hölscher (2014) in CNS Drugs demonstrated direct antidepressant-like effects of GLP-1 analogs independent of food intake — GLP-1 signalling in the hypothalamus appears to modulate corticotropin-releasing factor (CRF), a key stress hormone involved in major depression.

Alcohol Use and Addiction

Multiple observational studies and anecdotal reports from patients and addiction clinics have noted that GLP-1 agonists dramatically reduce cravings for alcohol, nicotine, and compulsive eating behaviours. Mechanistically, GLP-1 signalling blunts dopamine release in the nucleus accumbens in response to rewarding stimuli — effectively dampening the "wanting" signal that drives cravings.

An observational study (Klausen et al., 2022, Addiction) found that GLP-1 agonist-treated patients showed approximately 50% lower relapse rates over 12 months compared to matched controls not on these medications. Dedicated alcohol use disorder RCTs are ongoing.

Until recently, kidney-protective effects of GLP-1 agonists were observed incidentally in cardiovascular outcome trials. The FLOW trial (Perkovic et al., 2024, NEJM) was the first dedicated renal outcomes trial for a GLP-1 drug — and it was stopped early.

GLP-1 receptors in the kidney tubules and mesangial cells are thought to reduce inflammation and fibrosis — the primary drivers of progressive CKD. The benefit may compound with SGLT-2 inhibitors (like empagliflozin), which work via a complementary renal mechanism, and several combination trials are underway.

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and its inflammatory form MASH (formerly NASH) are increasingly common — affecting roughly 25% of the global population. GLP-1 agonists directly reduce hepatic fat accumulation via multiple pathways.

The ESSENCE trial (Harrison et al., 2024, NEJM) found semaglutide 2.4mg resolved MASH in 62.9% of treated patients vs 34.3% of placebo recipients — and achieved liver fibrosis improvement (≥1-stage) in 36.8% vs 22.4%.

Tirzepatide's SURMOUNT-NASH trial showed even stronger results: resolution of MASH in 44.4–62.4% of patients (dose-dependent) vs 9.7% for placebo, published in 2024. Both drugs have since received FDA approval or supplemental indications specifically for MASH treatment.

Obesity is the primary driver of obstructive sleep apnea (OSA) in most patients — so it was unsurprising when GLP-1 agonists, which drive significant weight loss, improved apnea-hypopnea index (AHI) scores. But two large RCTs suggest the effect may exceed what weight loss alone predicts.

The SURMOUNT-OSA trials (Malhotra et al., 2024, NEJM) enrolled 469 adults with moderate-to-severe OSA and obesity. Tirzepatide reduced AHI by approximately 27–30 events per hour — a ~60% reduction — compared to ~5 events/hour for placebo. Notably, even patients using CPAP machines showed meaningful improvement on tirzepatide vs placebo.

Proposed mechanisms beyond weight loss include reduced upper airway inflammation, changes in ventilatory control sensitivity, and possible direct GLP-1 receptor effects on airway smooth muscle. Tirzepatide received FDA approval for OSA in adults with obesity in June 2024.

All citations link to the primary source on PubMed or publisher DOI.

Related Reading